FRACTYL HEALTH, INC. (GUTS): restructuring charge — Fractyl Health prioritizes Revita weight maintenance, Rejuva gene therapy; cuts 17% workforce

FRACTYL HEALTH, INC.

REMAIN-1 pivotal study for weight maintenance post-GLP-1 withdrawal; midpoint data analysis expected Q2 2025, full enrollment summer 2025.
Rejuva gene therapy candidate RJVA-001 completed key preclinical studies; first-in-human studies planned H1 2025.
Pausing Revita T2D programs (REVITALIZE-1 and German Real-World Registry) to focus resources.
Workforce reduction of 22 employees (~17%) with estimated severance costs of $1.8M; cash runway extended into 2026.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

FRACTYL HEALTH, INC. announced a restructuring with charges of approximately $1.8 million affecting the Company (22 employees, or approximately 17% of the Company’s workforce).

Type: restructuring
Charge: approximately $1.8 million
Affected area: the Company
Headcount: 22 employees, or approximately 17% of the Company’s workforce

Exact text from the filing

implemented by the second quarter of 2025. In connection with the Strategic Reprioritization, the Company estimates that it will incur cash charges of approximately $1.8 million related to severance, employee benefits, and other related personnel reduction costs. At this time, the Company is unable in good faith to make a determination of other estimated

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

FRACTYL HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-011430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.